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RESULTS: The OPFx cohort (n = 7626) and a 1 :1 matched
control group with osteoporosis, but without a fracture were
identiﬁed. The OPFx cohort was 85.8% female, had an average
age of 65, were 53.2% White and 11.1% Asian, and 48.9% were
dual-eligible for Medicare. There were signiﬁcant increases (all
p < 0.05) from the pre-period to study-period for this cohort in
the proportion that had at least one hospital admission (12.0%
vs. 22.3%), nursing home admission (8.7% vs. 18.2%) or ER
visit (28.2% vs. 45.9%); in contrast, the control cohort had very
little variation in utilization. The regression-adjusted incremen-
tal cost in the year following fracture was estimated at $4007
per osteoporosis patient. The estimated incremental cost was
$5370 for the subset of patients who were dual-eligible. CON-
CLUSIONS: Osteoporosis-related fractures exhibit a tremen-
dous humanistic and economic toll in patients. The economic
burden of OPFx on state Medicaid budgets is substantial. Pre-
ventative strategies for avoiding fractures could help ameliorate
some of this burden.
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OBJECTIVES: To estimate impact of cardiovascular events on
annual health care costs in newly diagnosed type-2 diabetes
patients. METHODS: Patients with newly diagnosed type-2 dia-
betes (index event) between January, 1999 and December, 2001
were identiﬁed from an employer claims database using ICD-9
codes. In the absence of a diagnosis, patients were included 
if they had at least two claims for oral hypoglycemics in a 
six-month period. A cardiovascular event was deﬁned as emer-
gency/inpatient claims for one or more of 16 cardiovascular com-
plications identiﬁed. Patients with evidence of a cardiovascular
event in the 12 months preceding the index event were excluded.
Costs were adjusted to 2002 dollars and then annualized. A log-
transformed model was developed to estimate the impact of 
cardiovascular events on annual health care costs. Patient 
demographics, co-morbidities, concomitant medications and
treatment groups were used as covariates. RESULTS: Based on
the selection criteria, the study cohort included 57,563 newly
diagnosed type-2 diabetes patients. The average patient age was
59.5 years and 50.7% were female. The mean adjusted annual
health care cost per patient was $11,994.33. Annual cost was
distributed across emergency room (2.49%), outpatient (45%),
inpatient (29.75%) and prescription drug (22.54%) costs.
Annual costs were signiﬁcantly greater in women (17.1%; p <
0.001) and signiﬁcantly lower in absence of any complications
(-14.5%; p < 0.001). About 12% of the type-2 diabetes patient
population reported one or more cardiovascular events. The
mean number of cardiovascular events per patient per year 
was 0.067. A cardiovascular event contributed to a signiﬁcant
increase (129%; p < 0.001) in annual costs. The average annual
cost per patient ranged from $9,507 (zero CV event) to $65,130
(5+ CV events). CONCLUSIONS: Cardiovascular events con-
tribute signiﬁcantly to health care costs in the type-2 diabetes
patients.
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OBJECTIVE: To evaluate the sensitivity of overactive bladder
(OAB) medical cost estimates to estimation technique.
METHODS: Data were from de-identiﬁed medical and phar-
macy claims of patients aged ≥18 years enrolled in a large US
health plan. Inclusion criteria were: ≥1 claim with OAB-related
ICD-9-CM codes recorded between January 1, 2001 and Decem-
ber 31, 2002; initiation of immediate-release oxybutynin (OXY
IR), extended-release OXY (OXY ER), or extended-release
tolterodine (TOL ER); and continuous health plan coverage 
for six months before and 12 months after treatment initiation.
Models were based on logged 12-month medical costs, with
treatment, sex, age, geographic region, baseline costs, and
comorbidities as covariates. Estimation techniques compared
were ordinary least squares (OLS) with smearing estimator, treat-
ment regressions estimating the correlation between cost and
treatment, and two-stage instrumental variables (IV) regressions.
Selectivity-corrected models were estimated for OXY IR and
OXY ER, with TOL ER as the referent. RESULTS: Association
of treatment with cost varied with estimation technique. Com-
paring costs of TOL ER and OXY ER, coefﬁcients were OLS,
0.582 (t = 1.86, p = 0.063); treatment regression, 1.108 (Z =
3.93, p < 0.001); IV regression, 1.878 (Z = 3.27, p = 0.001). A
negative correlation between treatment and cost (p, -0.3842, 
p < 0.001) suggested that OLS estimates underestimated cost 
differences between TOL ER and OXY ER therapies. OXY ER
patients had one-year predicted medical costs 191% higher
(treatment regression) or 455% higher (IV regressions) than 
did TOL ER patients. The treatment regression correlation
between the TOL ER and OXY IR treatment groups was sig-
niﬁcant and negative, suggesting that OLS also underestimated
differences in cost between those cohorts. Treatment regression
analysis revealed that costs for OXY IR patients were 48%
higher than those for TOL ER patients. CONCLUSIONS:
Failing to adjust for selection bias when comparing OAB treat-
ment costs may lead to biased estimates of cost differences
between therapies.
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OBJECTIVE: Atrial ﬂutter (AFL) is a prevalent arrhythmia
among the elderly. While numerous clinical studies have shown
the safety and efﬁcacy of cardiac ablation, the ﬁrst-line approach
still varies among physicians. The study objective is to assess the
cost-utility of catheter ablation as ﬁrst-line treatment of typical
isthmus dependent AFL. METHODS: The incremental cost-
effectiveness of catheter ablation relative to cardioversion and
drug therapy was analyzed over various time horizons up to ﬁve
years using a decision analytic Markov model (DATA 4.0TM,
TreeAge Software Inc.). Costs were based on a third party payer’s
perspective using 2004 Medicare reimbursement schedules and
discounted average wholesale drug prices. Model parameters,
adverse event rates, and utility weight estimates were obtained
from published clinical trials. Costs and utilities were discounted
at 3% annually and sensitivity analyses were performed. The
model analyzed the outcomes and resource utilization of a hypo-
thetical cohort of patients with typical isthmus-dependent AFL.
RESULTS: Ablation consistently produced greater quality-
adjusted life years (QALYs) compared to cardioversion and
drugs in analyses of one to ﬁve years (0.78 to 3.57 vs. 0.66 to
2.93 QALYs). While initial treatment costs are higher for abla-
tion compared to cardioversion and drug therapy, ablation
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becomes the dominant strategy after 2.5 years due to its lower
long-term cost of care. The average cumulative one and ﬁve-year
costs are $10,855 and $12,866 for ablation compared to $5163
and $24,377 for cardioversion and drug therapy. Over a 5-year
time horizon, the cumulative QALY gain with catheter ablation
is 0.64 at a cost-savings of greater than $11,500. CONCLU-
SION: For ﬁrst-line treatment of typical isthmus-dependent 
AFL, catheter ablation is more effective and less costly than 
cardioversion and drug therapy.
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OBJECTIVES: The objective of this study was to estimate the
existing ﬁnancial costs from obesity in the United Kingdom (UK).
METHODS: This comprehensive study was undertaken using a
number of data sources that included a measure of height and
weight. Population data were taken from published UK govern-
mental sources. NHS hospital utilisation data from a region, in
addition to corresponding specialized survey data (Health out-
comes data repository [HODaR]). Cost data were taken from
statistical governmental series and published sources (HRGs).
Estimates of ﬁnancial cost—including direct, indirect and intan-
gible costs—were available from HODaR. All costs for all
disease categories were calculated for different groups deﬁned by
age, sex and body mass index (BMI). Resulting values in alter-
native categories were compared using the Mann-Whitney U test,
comparing overweight and obese patients with ‘normal’ groups.
Provided the test indicated a signiﬁcant difference to the normal
group, the amount of additional costs was calculated and termed
excess costs. Prices are in UK£, 2002. Unusually, this considered
all diseases including those where obesity provides a protective
affect e.g., osteoporosis. RESULTS: In UK in 2002 approxi-
mately 10.5 million adults age >18 years were obese (BMI 
>30kg/m2), equivalent to 22.9% of the population. Total direct
excess costs were estimated as £1.5 billion. Proportionally, the
most costly excess cost category occurred in the provision of
social services. The indirect costs due to work loss in the 18–54
year-old group accounted for £2.7 billion. The marginal excess
costs accounted for 2.3% of the total NHS budget. Furthermore,
quality of life was signiﬁcantly lower in obese people. CON-
CLUSIONS: These results conﬁrm the current heavy ﬁnancial
toll of obesity in the UK. Obesity is already a major health
problem in the UK and if recent trends of increasing BMI con-
tinue it will intensify.
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Kalsekar I1, Iyer S2, Mody R3, Rajagopalan R2, Kavookjian J3
1Butler University, Indianapolis, IN, USA; 2Takeda Pharmaceuticals
North America, Inc, Lincolnshire, IL, USA; 3West Virginia University,
Morgantown, WV, USA
OBJECTIVES: To compare the economic consequences of treat-
ment with either thiazolidinediones (TZD) or insulin in patients
with type-2 diabetes. METHODS: Type-2 diabetes patients ini-
tiating TZD or insulin treatment during the three-year period
(1999–2001) were identiﬁed from a Medicaid claims database.
The ﬁrst prescription for a TZD or insulin was treated as an
index prescription and health care costs in the 12-month follow-
up period were assessed. Analysis was restricted to a compliant
sample receiving at least six prescriptions of either TZD or
insulin. Propensity matching techniques were used to control for
selection bias and potential imbalances between the two treat-
ment groups. Semi-logarithmic OLS models were used to esti-
mate the impact of therapy on total and diabetes related health
care costs. The costs were also examined separately in terms of
Emergency Room (ER)/hospitalization, outpatient and prescrip-
tion costs using appropriate two-part models. Smearing esti-
mates were used to interpret the results from the semi-log
models. RESULTS: The propensity-matched sample consisted of
327 patients per treatment group with comparable demographic
and utilization parameters at baseline. In the 12-month follow-
up period, the TZD group incurred signiﬁcantly lower total
health care costs (19.1%; $10,606 vs. $13,062), ER/hospitaliza-
tion costs (58.2%; $2432 vs. $5826) and outpatient costs
(33.9%; $2672 vs. $4014) compared to the insulin group. The
TZD group also had signiﬁcantly lower diabetes related health
care costs (15.0%; $4877 vs. $5721), diabetes related ER/hos-
pitalization costs (69.1%; $1733 vs. $5613) and outpatient costs
(39.8%; $722 vs. $967) than the insulin group. The TZD group
had signiﬁcantly higher total (14.9%; $4687 vs. $4072) and dia-
betes related (63.0%; $1353 vs. $772) prescription costs. CON-
CLUSION: The results of the study suggest that despite its higher
acquisition cost, treatment with TZD signiﬁcantly reduces total
and diabetes-related health care costs as compared to insulin
therapy in patients with type-2 diabetes.
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OBJECTIVE: To determine the cost-effectiveness [CE] of non-
invasive myocardial perfusion imaging [MPI] in asymptomatic
individuals with diabetes mellitus [DM] for detection of CAD.
METHODS: A decision tree analysis using TreeAgeTM software
was completed to determine the probabilistic CE of MPI in com-
parison to stress echocardiography [ECHO] and do-nothing
management [DNM]. Probabilities for the analysis included
cardiac event incidence such as non-fatal MI and cardiac death
and percent of test results reported as abnormal/positive or
normal/negative for each diagnostic technique. Utilities consisted
of PPV and NPV values obtained from the published literature;
preference scores [zero to one scale] assigned to disease states
were similarly obtained. Medicare charges for 2004 were used
as surrogates of cost; mean charges for initial clinical assessment
[labs, etc.], exercise treadmill testing, ECHO, and MPI were all
included in the CEA. RESULTS: MPI demonstrated PPV of
92.9% in detecting CAD in asymptomatic patients with DM
compared to a stress ECHO PPV of 80%. However, ECHO is
the dominant strategy with a mean cost of $701 and effective-
ness ratio of 0.51. MPI demonstrated a mean cost of $1084 
with an effectiveness ratio of 0.60. The resulting ICER is
$4324/QALY. Importantly, DNM is dominated by MPI [p <
0.006] CONCLUSIONS: MPI is more effective and more costly
than stress ECHO but meets generally-regarded WTP thresholds
in asymptomatic individuals with DM. Use of diagnostic data
from MPI may impact clinical outcomes such as cardiac events
by inﬂuencing early management decisions.
